Skip to main content
. 2022 Apr 25;8:227. doi: 10.1038/s41420-022-00949-y

Fig. 2. JMJD2C is overexpressed in uveal melanoma and promotes CDDP resistance.

Fig. 2

A The expression of JMJD2C in uveal melanoma tissues as determined by RT-qPCR (uveal melanoma = 32, normal = 30). B The expression of JMJD2C in normal uveal epithelial cells ARPE-19, uveal melanoma cells MUM-2B, and drug-resistant cell line MUM-2B/CDDP as determined by RT-qPCR. C The protein expression of JMJD2C after sh-JMJD2C or oe-JMJD2C treatment in the MUM-2B/CDDP cells and MUM-2B cells, respectively, as measured by Western blot assay. D The cell viability and IC50 in MUM-2B/CDDP cells after JMJD2C silencing and MUM-2B cells after JMJD2C overexpression as assessed by CCK-8 assay. E The senescence rate of MUM-2B/CDDP cells after JMJD2C silencing and MUM-2B cells after JMJD2C overexpression as assessed by SA-β-gal staining. F The migration and invasion abilities of MUM-2B/CDDP cells after JMJD2C silencing and MUM-2B cells after JMJD2C overexpression as assessed by Transwell assay. * p < 0.05. Cell experiments were repeated three times independently.